Garner William
Founder chez GENETETHER THERAPEUTICS INC.
Fortune : 4 M $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jeffrey Bacha | M | 56 |
Del Mar Pharmaceuticals (BC) Ltd.
Del Mar Pharmaceuticals (BC) Ltd. Pharmaceuticals: MajorHealth Technology Part of Kintara Therapeutics, Inc., Del Mar Pharmaceuticals (BC) Ltd. provides drug development services. The private company is based in Vancouver, Canada. The Canadian company was founded by William James Garner, Jeffrey A. Bacha, Dennis M. Brown. Jeffrey A. Bacha has been the CEO since incorporation. Del Mar Pharmaceuticals (BC was acquired by Kintara Therapeutics, Inc. on January 25, 2013 for $0.65 million. | 15 ans |
Daren Graham | M | 52 |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California.
EGB Ventures LLC
EGB Ventures LLC Investment ManagersFinance EGB Ventures LLC EGB Ventures) is a venture capital firm founded in 2010 by William (Bill) Garner. The firm is headquartered in Whitewright, Texas. | 6 ans |
R. Geoffrey Sargent | M | 70 |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | 6 ans |
Dennis Brown | M | 74 |
Del Mar Pharmaceuticals (BC) Ltd.
Del Mar Pharmaceuticals (BC) Ltd. Pharmaceuticals: MajorHealth Technology Part of Kintara Therapeutics, Inc., Del Mar Pharmaceuticals (BC) Ltd. provides drug development services. The private company is based in Vancouver, Canada. The Canadian company was founded by William James Garner, Jeffrey A. Bacha, Dennis M. Brown. Jeffrey A. Bacha has been the CEO since incorporation. Del Mar Pharmaceuticals (BC was acquired by Kintara Therapeutics, Inc. on January 25, 2013 for $0.65 million. | 15 ans |
Gage Jull | M | 64 |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | 4 ans |
Phillip Lynch | M | - | 4 ans | |
Roland Boivin | M | 57 |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | 3 ans |
James Kuo | M | 58 | 5 ans | |
James Gilligan | M | 72 | 4 ans | |
Peter Molloy | M | 52 | 4 ans | |
Peter Laurence Molloy | M | 70 |
Innovation Angel Foundation, Inc.
| 13 ans |
Jean Jen | F | 37 |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | 3 ans |
Andrew Hull | M | 61 | 8 ans | |
Andre Pereira Fraga Figueiredo | M | 48 |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | 3 ans |
Borje Andersson | M | - | 4 ans | |
Nicole Lemerond | F | 49 | 2 ans | |
Bryan Baldasare | M | 58 | 2 ans | |
Michael Woudenberg | M | - | 6 ans | |
Janet Grove | F | 57 | 2 ans | |
Robert Toth | M | 60 | 11 ans | |
Jay R. Campbell | M | - |
Update Pharma, Inc.
Update Pharma, Inc. Medical DistributorsDistribution Services Part of MDM Permian, Inc., Update Pharma, Inc. develops and provides anti-cancer drugs and other pharmaceutical products. The American company was founded by William James Garner. Update Pharma was acquired by BestnPet, Inc. on September 09, 2013. | - |
Marinella Messina | M | - | 4 ans | |
Peter Guzzo | M | - | 4 ans | |
Eric Hsu | M | - | 6 ans | |
Gerard Griffin | M | - | 2 ans | |
Green Joseph | M | - |
EGB Ventures LLC
EGB Ventures LLC Investment ManagersFinance EGB Ventures LLC EGB Ventures) is a venture capital firm founded in 2010 by William (Bill) Garner. The firm is headquartered in Whitewright, Texas. | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
David Guest | M | 53 | 2 ans | |
Lisa Guise | F | 56 | 2 ans | |
Gregory Collier | M | - | 6 ans | |
Sazzad Hossain | M | - | 38 ans | |
Martin E. Shmagin | M | 74 |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent.
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 4 ans |
Erich Mohr | M | 70 | 3 ans | |
Richard A. Bond | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | 8 ans |
Daniel Tillett | M | - | 4 ans | |
Jonathan Tegge | M | 34 | 2 ans | |
Stephen Ruoss | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Brian O'Connor | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Catherine A. Sazdanoff | F | 68 | 3 ans | |
Martin Bott | M | - | 2 ans | |
Terese Gieselman | F | 62 | 7 ans | |
Adam Daniel Cutler | M | 50 | 7 ans | |
Jeffrey Charpentier | M | - | - | |
Thomas Jurgensen | M | 66 |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | 8 ans |
John Bell | M | 77 | - | |
Mitchell Glass | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | 7 ans |
Michael Bristow | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Edward R. Teitel | M | 75 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 3 ans |
John Cullity | M | - | 5 ans | |
Scott Praill | M | 58 | 10 ans | |
Gregory M. McKee | M | 60 | 1 ans | |
Felix Shardonofsky | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Lynda Cranston | F | 77 | - | |
Brian Kobilka | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Brenda Edwards | F | - | - | |
Harpreet Grover | M | - |
GeneTether, Inc.
GeneTether, Inc. Miscellaneous Commercial ServicesCommercial Services GeneTether, Inc. develops gene editing technologies intended for human therapeutic applications. Its platform is focused on the treatment of rare, monogenic diseases of the kidney and the skin. The company was founded by William James Garner, R. Geoffrey Sargent, and Daren N. Graham on February 12, 2018 and is headquartered on California. | - |
John Moore | M | - | 1 ans | |
Peter Sampson | M | - | 2 ans | |
Christopher Ntoumenopoulos | M | - | 4 ans | |
Brendan de Kauwe | M | 46 | - | |
Joy Willis | F | - | 1 ans | |
Samar Al-Behaisi | M | - | - | |
Gordon Beck | M | - | - | |
Mike M. Goldberg | M | 65 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 1 ans |
Damon N. Sweeny | M | - | - | |
Cynthia L. Sullivan | F | 68 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 2 ans |
Luke Hayes | M | - | - | |
George Lasezkay | M | 72 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 5 ans |
Heather Giles | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | - |
Amie E. Franklin | M | - |
Inverseon, Inc.
Inverseon, Inc. Pharmaceuticals: MajorHealth Technology Inverseon, Inc. is a private company developing a re-profiled beta blocker for the treatment of asthma and COPD. Inverseon’s scientific approach, “Paradoxical Pharmacology”, is based on observations that chronic effects of inverse agonist drugs are completely opposite to their acute effects. A similar paradigm shift occurred in the late 1990’s with the approval of the first beta blocker for congestive heart failure, a disease state where the drug was also originally contraindicated. Inverseon’s scientific founder, Professor Richard Bond, identified the mechanism of action as inverse agonism at the beta adrenergic receptor and hypothesized that this observation represented a general pharmacological phenomenon and identified asthma as another disease to target. To date, the company has achieved a number of important milestones: completing two open-label Phase 2a studies demonstrating a dose-response, a comment in The Lancet in 2009 highlighting the published human clinical trial, and 2009 issuance of their first U.S. patent. | 8 ans |
Dennis Giesing | M | - |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 1 ans |
Robert J. Watkins | M | 81 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 3 ans |
Bruce Colwill | M | - | 3 ans | |
Joshua Blacher | M | 52 | - | |
John M. Rothman | M | 75 | - | |
Benjamin McGraw | M | 75 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Patrick Enright | M | 62 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Terry M. Nida | M | - |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | 13 ans |
Tracy B. Taylor | M | 69 |
Vaneltix Pharma, Inc.
Vaneltix Pharma, Inc. Pharmaceuticals: MajorHealth Technology Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on the development and commercialization of innovative products for urology indications. It is specialized in the design and implementation of products for patients with urological ailments, including products for amelioration of bladder pain syndrome and interstitial cystitis. The company was founded in March 1999 and is headquartered in North Brunswick, NJ. | - |
Sarah Li | F | - | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 40 | 50,63% |
Canada | 34 | 43,04% |
Australie | 15 | 18,99% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Garner William
- Réseau Personnel